Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography- Magnetic Resonance Imaging (FDG-PET-MRI) in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Inclusion Criteria:

- Diagnosed with neurofibromatosis-1 with either optic glioma, due for imaging scan, or
plexiform neurofibroma, due for imaging secondary to clinical signs or symptoms of
progressive disease

- ≥ 6 years of age

- English-speaking

- If female of child-bearing potential, negative urine pregnancy test performed within
7 days prior to each FDG-PET-MRI

- Study-specific informed consent or assent obtained and signed

Exclusion Criteria:

- Unable to undergo FDG-PET-MRI without sedation

- Currently undergoing chemotherapy for progressing optic glioma

- Pregnant or lactating female

- Poorly controlled diabetes mellitus

- Presence of pacemaker, intracranial aneurysm clip, cochlear implant, metal halo
device, epicardial pacemaker leads, or any other device that makes MRI unsafe

- Serum creatinine > 1.8 mg/dL OR GFR < 30 mL/min

- Unable to lie flat for > 1 hour

- Body Mass Index (BMI) > 35